Clinical trial
Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
NCT02459899
Study timeline
Study start (actual)2015-07-01Date precision: month
Registry last updated2020-02-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 1 Diabetes Mellitusunresolved
Interventions
PlaceboDRUG
SotagliflozinDRUG · verified · RxNorm: sotagliflozin
Sponsors & collaborators
Lexicon Pharmaceuticalslead sponsor
Sanoficollaborator
Mapped research locations
MiamiFlorida, United States1San AntonioTexas, United States1ColumbusOhio, United States1JacksonvilleFlorida, United States1DenverColorado, United States1OmahaNebraska, United States1Salt Lake CityUtah, United States1SpringfieldIllinois, United States1RockvilleMaryland, United States1MetairieLouisiana, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02459899 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.